Is AI Biased Toward "Exceptional Responders?"
Source: Clinical Leader
Ram Mukunda of IGC Pharma poses a question to Michael Lingzhi Li of Harvard about the risks of using AI to identify only on a small subset of patients who would then be enrolled in a clinical trial.
        access the Video!
        
            Log In
        
    
    
    
    Get unlimited access to:
            Trend and Thought Leadership Articles
            
        
        
            Case Studies & White Papers
            
        
        
            Extensive Product Database
            
        
        
            Members-Only Premium Content
            
        
    
        Welcome Back! Please Log In to Continue.
        
            X
        
    
    Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
        Subscribe to Clinical Leader
        X
    
    
        Subscribe to Clinical Leader